Side-by-side · Research reference

TestagenvsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED11/41 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

Testagen

Bioregulator Peptide · Khavinson School

Lys-Glu-Asp-GlySequenceFedoreyeva 2011

NuclearLocalizationFedoreyeva 2011

TesticularTissue target

SQ · Abdomen · Cyclical

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

Testagen

Vesugen

Primary target

Testicular tissue; proposed nuclear DNA interaction

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

Unknown — no HPG axis data

Not applicable — does not operate via hormone axis

Origin

Khavinson bioregulator school — isolated from testicular tissue peptide fractions

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

Testagen

Vesugen

Typical protocol (anecdotal)

100–200 mcg / day

No published human dosing studies; derived from Russian bioregulator practice.

—

Frequency

Once daily or alternate days

Not specified in available literature

Cycle length

10–20 days on, 10–14 days off

Bioregulator tradition uses pulsed cycles; no controlled data.

—

Evidence basis

Animal mechanistic / in vitro onlyFedoreyeva 2011

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Route

Subcutaneous

Subcutaneous or intramuscular

Reconstitution

Sterile water or bacteriostatic saline

—

Half-life

Unknown — likely minutes (short peptide)

Not reported

Tripeptides typically cleared rapidly.

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Duration

—

Case series report treatment courses in elderly arterial insufficiency

04Side Effects & Safety

Parameter

Testagen

Vesugen

Injection site reactions

Erythema, mild irritation (potential)

—

Systemic effects

Unknown — no human safety data

—

Hormonal impact

No published data on testosterone, LH, FSH effects

—

Long-term safety

Unknown — no long-term studies

Unknown — no long-term RCT data

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

Testagen

·Active testicular malignancy

Vesugen

—

Relative Contraindications

Testagen

·Hormone-sensitive cancers (no data; theoretical caution)
·Pregnant or breastfeeding (no data)

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

Testagen

Vesugen

1. Reconstitution

Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Timing

Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Storage

Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Cycle protocol

10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.

—

06Stack Synergy

Testagen

— no documented stacks

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)